The IV glutathione drip is the route with the least evidence and the most warnings. Oral and topical glutathione show modest lightening, mostly on sun-exposed skin, that fades after stopping. The only placebo-controlled IV trial missed significance, and FDA has documented serious reactions when compounders used supplement-grade material.
Key points
- In the first oral trial (60 students, 4 weeks), glutathione was associated with a lower melanin index than placebo at 2 of 6 measured sites [2].
- Systematic reviews describe a modest effect, mainly on sun-exposed skin, that does not last after stopping the product [4][5].
- For the intravenous route there is a single placebo-controlled trial: 37.5% vs 18.7% response, p = 0.054 [5].
- The Philippine FDA warned in 2019 that there were no published trials of injectable glutathione for skin lightening [7]; the US FDA has documented serious reactions to supplement-grade glutathione in intravenous preparations [8][9].
- The antidote for acetaminophen is N-acetylcysteine, a glutathione precursor. IV glutathione is not the antidote [12].
US status (October 2026): See the peptide status tracker.
A tripeptide turned beauty treatment
Glutathione is a tripeptide made of cysteine, glycine and glutamate, synthesized by the body and one of its main antioxidants [15]. Its cosmetic use rests on a plausible mechanism: blocking the tyrosinase pathway and shifting melanogenesis toward pheomelanin, a lighter pigment [6]. It is sold in oral, topical and intravenous forms, and its use as a lightening supplement is common in Asia [4]. Dermatologists who have reviewed it describe a phenomenon driven by marketing and especially widespread among people with darker skin [1].
The IV route is usually offered alongside other cosmetic drips. The same pattern abroad is covered in Panama’s Law 491, drips and mycobacteria, and the US claims problem in NAD+ IV therapy claims. This article covers what the studies show about skin color.
Oral and topical trials show a modest effect
The first randomized, double-blind trial was run in Bangkok with 60 medical students who took 500 mg/day of glutathione or placebo for 4 weeks. The melanin index fell at all six measured sites with glutathione, but the difference versus placebo was significant at only two: the right side of the face (p = 0.021) and the sun-exposed forearm (p = 0.036). Both products were well tolerated, and the authors noted that long-term safety had not been established [2].
A second trial by the same group compared 250 mg/day of reduced glutathione, 250 mg/day of oxidized glutathione and placebo for 12 weeks in healthy women. Melanin index and UV spots “tended” to be lower with both forms. The reduced form was associated with fewer wrinkles at some sites, with no serious adverse effects [3]. Topically, a 2% oxidized glutathione lotion applied to half the face for 10 weeks was associated with a lower melanin index than placebo on the other half (p < 0.001) in 30 women. Industry authors ran that study [15].
- 60: students in the first oral trial; significant effect at 2 of 6 sites [2]
- p = 0.054: the only placebo-controlled intravenous trial, 37.5% vs 18.7% [5]
- ≥ 30: patients with adverse events from supplement-grade IV glutathione, FDA 2026 [9]
Systematic reviews read these data cautiously. The 2019 review included four studies and concluded that the lightening effect “is still inconclusive”, with a trend toward lightening sun-exposed skin and no differences on protected skin [4]. The 2025 review counted five randomized oral trials with significant reductions in melanin index, but rated oral and topical results as moderate and not sustainable over time [5].
The IV drip has one controlled trial, and it missed significance
The best-selling route has the least evidence. According to the 2025 review, there is a single placebo-controlled study of intravenous glutathione: response in 6 of 16 patients (37.5%) vs 3 (18.7%), p = 0.054, not statistically significant. The review authors concluded that the intravenous route is contraindicated for this purpose because of lack of efficacy and adverse effects [5]. A 2018 review described that same trial as having a “dubious” design and an apparently flawed analysis [1].
A 2026 narrative review adds a problem of interpretation. IV glutathione is usually given together with vitamin C, which makes its independent effect impossible to know. The review also mentions signals of hepatotoxicity, hypersensitivity and possible renal and endocrine effects, and concludes that the evidence is too limited to justify routine cosmetic use [6].
Regulators in the Philippines and the US have issued warnings
On 5 July 2019 the Philippine FDA issued Advisory No. 2019-182. It stated that there were no published clinical trials of injectable glutathione for skin lightening and no guidelines on dose or duration, and that in that country injectable glutathione is approved as an adjunct to cisplatin chemotherapy. The risks it listed included liver, kidney and nervous-system toxicity, possible Stevens-Johnson syndrome, kidney stones from the intravenous vitamin C often given with it, hemodialysis after high-dose vitamin C in patients with G6PD deficiency, and transmission of HIV and hepatitis when given in non-sterile settings [7].
In the United States, the documented problem has been ingredient quality. In 2019 the FDA warned compounding pharmacies not to use a lot of glutathione powder labeled as a dietary supplement. Seven outpatient-clinic patients who received 1,400 mg intravenously developed nausea, vomiting, chills and lightheadedness within minutes, and one was hospitalized [8]. In August 2026 the agency reported at least 30 patients with fever, chills, signs of shock and sepsis-like symptoms after IV glutathione compounded from supplement-grade material, consistent with endotoxin exposure [9].
If you run an IV menu, the grade of the active ingredient is your first question to the pharmacy. See 503A vs 503B sourcing and what is really in the vial.
Studied medical uses, and a common confusion
Outside aesthetics, parenteral glutathione is registered in some countries for severe liver disease and to prevent chemotherapy neurotoxicity [1]. In Parkinson’s disease it has been studied with negative results. A pilot trial in 21 patients given 1,400 mg intravenously three times a week for 4 weeks showed no significant differences on the UPDRS scale (2.8 points in favor, p = 0.32) [10]. A phase IIb trial in 45 patients using intranasal glutathione for three months was also not superior to placebo, and one participant in the high-dose group developed cardiomyopathy [11].
Drip advertising often presents glutathione as “the acetaminophen antidote”. The antidote is N-acetylcysteine, which supplies the cysteine the liver needs to make its own glutathione. According to a pharmacology review, its strength is replenishing glutathione in deficient cells, and it is likely ineffective in cells with normal stores [12]. Remove that claim from any menu or ad you sign off on.
Oral absorption data are mixed
The classic doubt was whether oral glutathione survives digestion [4]. A 4-week trial of 1,000 mg/day in 40 healthy adults found no change in oxidative-stress markers or erythrocyte glutathione [14]. A 6-month trial in 54 adults showed 30 to 35% increases in glutathione in erythrocytes, plasma and lymphocytes with the high dose; levels returned to baseline after one month off the supplement [13].
The other side. Oral and topical glutathione have more support than many cosmetic products. Five randomized oral trials were associated with significant reductions in melanin index versus placebo [5], and the 2% lotion showed differences from the first weeks [15]. The oral trials recorded no serious adverse effects [2][3], the rise in body stores with prolonged use is documented [13], and IV use in Parkinson’s was well tolerated with no safety concerns identified [10]. The 2019 systematic review found a trend toward lightening sun-exposed skin [4]. Patient demand is real. A clinician who knows the difference between the oral and IV routes can guide it with data.
What this means for you
Treat IV glutathione for skin lightening as an unsupported indication. If patients ask, the oral and topical data are the honest conversation. If you offer IV glutathione for any reason, confirm in writing that the pharmacy does not use supplement-grade material, and keep acetaminophen-antidote language out of your marketing. For how an IV service line is structured, see IV therapy.
References
- Sonthalia S, et al. Glutathione for skin lightening: a regnant myth or evidence-based verity? Dermatol Pract Concept. 2018;8(1):15-21. PMID 29445569. Link
- Arjinpathana N, Asawanonda P. Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. J Dermatolog Treat. 2012;23(2):97-102. PMID 20524875. Link
- Weschawalit S, et al. Glutathione and its antiaging and antimelanogenic effects. Clin Cosmet Investig Dermatol. 2017;10:147-153. PMID 28490897. Link
- Dilokthornsakul W, et al. The clinical effect of glutathione on skin color and other related skin conditions: A systematic review. J Cosmet Dermatol. 2019;18(3):728-737. PMID 30895708. Link
- Sarkar R, et al. Glutathione as a skin-lightening agent and in melasma: a systematic review. Int J Dermatol. 2025;64(6):992-1004. PMID 39444151. Link
- Aloraini K, et al. Glutathione for skin lightening via intravenous, oral, and topical routes: a critical narrative review of current evidence, safety, and the evidence-practice gap. J Med Life. 2026;19(7):511-523. PMID 42751591. Link
- Food and Drug Administration of the Philippines. FDA Advisory No. 2019-182: Unsafe use of glutathione as skin lightening agent. 5 July 2019 (archived copy). Link
- U.S. FDA. FDA highlights concerns with using dietary ingredient glutathione to compound sterile injectables. Compounding Alert, 7 June 2019. Link
- U.S. FDA. FDA reminds compounders not to use dietary supplement grade glutathione for injectables. 27 August 2026. Link
- Hauser RA, et al. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson’s disease. Mov Disord. 2009;24(7):979-83. PMID 19230029. Link
- Mischley LK, et al. Phase IIb Study of Intranasal Glutathione in Parkinson’s Disease. J Parkinsons Dis. 2017;7(2):289-299. PMID 28436395. Link
- Rushworth GF, Megson IL. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol Ther. 2014;141(2):150-9. PMID 24080471. Link
- Richie JP Jr, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr. 2015;54(2):251-63. PMID 24791752. Link
- Allen J, Bradley RD. Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. J Altern Complement Med. 2011;17(9):827-33. PMID 21875351. Link
- Watanabe F, et al. Skin-whitening and skin-condition-improving effects of topical oxidized glutathione: a double-blind and placebo-controlled clinical trial in healthy women. Clin Cosmet Investig Dermatol. 2014;7:267-74. PMID 25378941. Link
This is general information, not medical or legal advice. Rules vary by state and change. Confirm your own facts with counsel.